Ascendis Pharma A/S
TransCon IL-2 ß/ g + weekly paclitaxel
late-line platinum-resistant ovarian cancer (PROC)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for TransCon IL-2 ß/ g + weekly paclitaxel in late-line platinum-resistant ovarian cancer (PROC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“Expect to report median overall survival (OS) data for a cohort of 70 patients with late-line platinum-resistant ovarian cancer (PROC) from the IL-Believe Trial of TransCon IL-2 ß/ g + weekly paclitaxel in the second quarter of this year.”